Opus Genetics (IRD) Return on Capital Employed (2018 - 2026)
Opus Genetics (IRD) posted quarterly Return on Capital Employed of 87.51% for Q1 2026, up 26453.0% year-over-year from N/an in Q1 2025, and up 19.74% quarter-over-quarter from 109.03% in Q4 2025.
Opus Genetics (IRD) Return on Capital Employed (2018 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Return on Capital Employed for 9 consecutive years, with 87.51% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 26453.0% year-over-year to 87.51%; the TTM figure through Mar 2026 stood at 87.51% (up 26453.0% YoY), while the FY2025 annual figure was 107.9%, up 7408.0% from the prior year.
- Return on Capital Employed climbed to 87.51% in Q1 2026 per IRD's latest filing, from 109.03% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 64.73% in Q3 2023 and bottomed at 784.63% in Q3 2025.
- Historically, Return on Capital Employed has averaged 129.66% across 5 years, with a median of 87.51% in 2026.
- Annual changes were most pronounced in 2025 — Return on Capital Employed plunged 70393 bps — and 2026, when it jumped 26453 bps.
- Opus Genetics' Return on Capital Employed stood at 62.79% in 2022, then sank by 134 bps to 21.11% in 2023, then plunged by 976 bps to 227.12% in 2024, then jumped by 52 bps to 109.03% in 2025, then grew by 20 bps to 87.51% in 2026.
- Business Quant data shows IRD's Return on Capital Employed at 87.51% in Q1 2026, 109.03% in Q4 2025, and 784.63% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | -70.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -70.02% |
| Mar 31, 2026 | -87.51% |
| Dec 31, 2025 | -109.03% |
| Sep 30, 2025 | -784.63% |
| Jun 30, 2025 | -279.34% |
| Mar 31, 2025 | -352.04% |
| Dec 31, 2024 | -227.12% |
| Sep 30, 2024 | -80.70% |
| Jun 30, 2024 | -34.16% |
| Mar 31, 2024 | -25.77% |
| Dec 31, 2023 | -21.11% |
| Sep 30, 2023 | 64.73% |
| Jun 30, 2023 | 46.94% |
| Mar 31, 2023 | 43.22% |
| Dec 31, 2022 | 62.79% |
| Sep 30, 2022 | -163.44% |
| Jun 30, 2022 | -137.39% |
| Mar 31, 2022 | -119.73% |
| Dec 31, 2021 | -109.23% |
| Sep 30, 2021 | -141.63% |